AbCellera Biologics Inc. (ABCL)
NASDAQ: ABCL · Real-Time Price · USD
11.36
+0.08 (0.71%)
At close: Sep 2, 2026, 4:00 PM EDT
11.32
-0.04 (-0.35%)
After-hours: Sep 2, 2026, 7:55 PM EDT
AbCellera Biologics Stock Forecast
Stock Price Forecast
According to 9 analysts polled by S&P Global, AbCellera Biologics stock has a consensus rating of "Strong Buy" and an average price target of $17.13. The average 1-year stock price forecast is 50.79% higher than the current stock price, while the lowest is $9.00 (-20.77%) and the highest is $30 (+164.08%).
Price Target: $17.13 (+50.79%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for AbCellera Biologics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 7 | 7 | 8 | 8 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 9 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Financial | Truist Financial | Buy Reiterates $30 | Buy | Reiterates | $30 | +164.08% | Sep 2, 2026 |
| BMO Capital | BMO Capital | Buy Maintains $15 | Buy | Maintains | $15 | +32.04% | Aug 18, 2026 |
| JonesTrading | JonesTrading | Buy Reiterates $13 → $25 | Buy | Reiterates | $13 → $25 | +120.07% | Aug 10, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $12 | Buy | Maintains | $12 | +5.63% | Aug 7, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $11 → $12 | Buy | Reiterates | $11 → $12 | +5.63% | Aug 6, 2026 |
Financial Forecast
Revenue This Year
25.25M
from 75.13M
Decreased by -66.39%
Revenue Next Year
25.01M
from 25.25M
Decreased by -0.94%
EPS This Year
-0.66
from -0.49
EPS Next Year
-0.72
from -0.66
EPS and Forward PE are based on non-GAAP adjusted numbers.